Guru Sonpavde

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. Sonpavde G, Sternberg C, Rosenberg J, Hahn N, Galsky M, Vogelzang N. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11:861-70 pubmed publisher
    ..A multidisciplinary approach is necessary to make therapeutic advances. This review discusses current second-line therapy and emerging drugs for advanced transitional-cell carcinoma. ..
  2. Sonpavde G, Matveev V, Burke J, Caton J, Fleming M, Hutson T, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012;23:1803-8 pubmed publisher
    ..In a subgroup of high-risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months). AT-101 was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high-risk patients. ..
  3. Sonpavde G, Watson D, Tourtellott M, Cowey C, Hellerstedt B, Hutson T, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012;10:1-5 pubmed publisher
    ..9% of patients who presented with AJCC stage 4 UC in a community-based cancer center network. Drug development focused on tolerable single-agent therapy or combination regimens without a cisplatin backbone should be a priority. ..
  4. Sonpavde G, Hutson T, Roth B. Management of recurrent testicular germ cell tumors. Oncologist. 2007;12:51-61 pubmed
    ..Salvage surgical resection has an important role in selected patients. Cisplatin-refractory patients have a poor prognosis with current therapy, and novel chemotherapeutic and biologic agents need to be discovered for such patients. ..
  5. Sonpavde G, Pond G, Berry W, de Wit R, Armstrong A, Eisenberger M, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30:607-13 pubmed publisher
    ..An increase in ALP by day 90 was also predictive of poor survival independent of ?50% PSA increase. Given the ready availability of ALP, the validation of our data is warranted. ..

Locale

Detail Information

Publications5

  1. Sonpavde G, Sternberg C, Rosenberg J, Hahn N, Galsky M, Vogelzang N. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11:861-70 pubmed publisher
    ..A multidisciplinary approach is necessary to make therapeutic advances. This review discusses current second-line therapy and emerging drugs for advanced transitional-cell carcinoma. ..
  2. Sonpavde G, Matveev V, Burke J, Caton J, Fleming M, Hutson T, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012;23:1803-8 pubmed publisher
    ..In a subgroup of high-risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months). AT-101 was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high-risk patients. ..
  3. Sonpavde G, Watson D, Tourtellott M, Cowey C, Hellerstedt B, Hutson T, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012;10:1-5 pubmed publisher
    ..9% of patients who presented with AJCC stage 4 UC in a community-based cancer center network. Drug development focused on tolerable single-agent therapy or combination regimens without a cisplatin backbone should be a priority. ..
  4. Sonpavde G, Hutson T, Roth B. Management of recurrent testicular germ cell tumors. Oncologist. 2007;12:51-61 pubmed
    ..Salvage surgical resection has an important role in selected patients. Cisplatin-refractory patients have a poor prognosis with current therapy, and novel chemotherapeutic and biologic agents need to be discovered for such patients. ..
  5. Sonpavde G, Pond G, Berry W, de Wit R, Armstrong A, Eisenberger M, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30:607-13 pubmed publisher
    ..An increase in ALP by day 90 was also predictive of poor survival independent of ?50% PSA increase. Given the ready availability of ALP, the validation of our data is warranted. ..